Editor’s note: I have myoclonic seizures too which I’ve spoken of in documentaries (I’ve fought them for some time) which is why I’m so hoping the medical cannabis amendment 2 passes here in Florida.
Here’s good news for the 30,000 Americans who suffer from a rare form of epilepsy…
The London-based company, GW Pharmaceuticals, is developing a pharmaceutical-grade form of cannabidiol (an oil found in marijuana) which will only contain trace amounts of tetrahydrocannabinol (THC), the component that makes you high. The drug, called Epidiolex, is expected to help patients with a rare form of epilepsy.
GW breeds its plants to produce lots of CBD and very little THC in greenhouses in England, and then purifies its oil using a manufacturing process. In fact, chief executive, Justin Gower says that the product is essentially pure CBD.
With the introduction of this product to market, the pharmaceutical company is now a part of the continuing debate about the use of marijuana for medial purposes. It’s been proven that CBD can help some kids with epilepsy so the question becomes whether or not it should ever be home grown, or if only BigPharma is allowed to prepare the healing oil. Should we have to be cut out of the process so that companies can make money off our sickness? Well, let the games begin; another firm, Insys Therapeutics, is now developing a fully synthetic form of CBD. From the article:
“In March, GW posted results of another study of Epidiolex that showed it was effective in Dravet syndrome, a form of epilepsy that afflicts just 6,000 children in the U.S. That result led GW Pharmaceuticals shares to surge 120% in a day to $85.
Today’s news is that Epidiolex showed similar efficacy in a second clinical trial, for a second rare epilepsy, Lennox Gastaut Syndrome, which afflicts both children and adults. The average patient in the study was having 74 seizures that resulting in hitting the floor a month. Eighty-six patients received Epidiolex on top of their current epilepsy medications, and 85 received placebo. Those receiving Epidiolex saw seizures reduced 44%, compared to a 22% reduction for those in placebo.”
The drug does have side effects. The seventy-four patients on Epidiolex had some event, compared to the 59 in the placebo group. The side effects included: diarrhea, sleepiness, decreased appetite and vomiting- though most side effects were mild or moderate.
GW Pharmaceuticals plans to file with the FDA for approval in the first half of 2017 for both Lennox Gastaut and Dravet, which will require that the second study they are currently doing on Lennox Gastaut, is positive. The company is currently doing a second study on Dravet although it’s not required for approval.
As you can imagine, shares in GW Pharmaceuticals are up just 10% to $92, based on the news. But analysts at Leerink, an investment bank, believe that GW will have annual sales of $1.2 billion by 2022, though not everyone agrees.
We are happy to see this finally get the respect and recognition that it deserves. Obviously, we in the alternative health community have known how well it works for a long time, but- better late than never. We will watch this story as it continues to unfold and update you when we have additional information.
Erin Elizabeth is a long time activist with a passion for the healing arts, working in that arena for a quarter century. Her site HealthNutNews.com is barely 4 years old, but cracked the top 20 Natural Health sites worldwide. She is an author, public speaker, and has recently done some TV and film programs for some of her original work which have attracted international media coverage. Erin was the recipient for the Doctors Who Rock "Truth in Journalism award for 2017. You can get Erin’s free e-book here and also watch a short documentary on how she overcame vaccine injuries, Lyme disease, significant weight gain, and more. Follow Erin on Facebook, Twitter, and Instagram.
P.S. You can subscribe to her Youtube Channel for breaking news, television appearances and more.